Patrick Daly

DocwireNews

Investigators, led by Naveen Pemmaraju, evaluated the toxicities and risk-adjusted safety of pacritinib, a novel JAK2/IRAK1 inhibitor, against best available therapies in patients with myelofibrosis. According to their poster, featured at the 2022 American Society of Clinical Oncology Annual Meeting, the safety profile of pacritinib was &ldquo;comparable or superior&rdquo; to best available therapies, including ruxolitinib.Patients in the study were a treated with pacritinib 200 mg twice a day. The risk-adjusted rate of overall and fatal adverse events (AEs), bleeding AEs, cardiac AEs, major cardiac events (MACE), infections, thrombosis, and secondary malignancies.The pacritinib group was comprised of 160 patients, and the best available therapy group had 98 patients, 44 of which were on ruxolitinib. Notably, the rate of AEs was higher for pacritinib compared to best available therapy, but the rate of fatal AEs was lower. Bleeding and cardiac AEs were slightly lower on pacritinib. The rate of malignant neoplasms was comparable between the groups, though non-melanoma skin cancers occurred less frequently with pacritinib.Ultimately, the authors judged that pacritinib at 200 mg two times a day &ldquo;may represent a full-dose therapeutic option for patients with myelofibrosis, including those with thrombocytopenia.&rdquo;

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Safety of Pacritinib Versus Best Available Therapies in Patients with Myelofibrosis

ASCO 2022

Investigators, led by Naveen Pemmaraju, evaluated the toxicities and risk-adjusted safety of pacritinib, a novel JAK2/IRAK1 inhibitor, against best available therapies in ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe